Express News | Dr. Reddy's Signs Non-Exclusive Patent Licensing Agreement With Takeda To Commercialize Vonoprazan In India
Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading
Asian equities traded in the US as American depositary receipts were tumbling sharply lower Wednesday morning, falling 1.84% to 2,004.10 on the S&P Asia 50 ADR Index.From North Asia, the gainers
Asian Equities Traded in the US as American Depositary Receipts Move Modestly Higher in Tuesday Trading
Asian equities traded in the US as American depositary receipts were trending modestly higher Tuesday morning, rising 0.30% to 2,037.69 on the S&P Asia 50 ADR Index.From North Asia, the gainers were
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading
Asian equities traded in the US as American depositary receipts started the week on a down note Monday morning, declining 0.89% to 2,039.03 on the S&P Asia 50 ADR Index.From North Asia, the gainers
Asian Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher in Monday Trading
Asian equities traded in the US as American depositary receipts opened the week trending slightly higher Monday morning, rising 0.14% to 2,020.67 on the S&P Asia 50 ADR Index.From North Asia, the gain
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
Asian equities traded in the US as American depositary receipts were trading lower Friday morning, declining 0.46% to 2,010.90 on the S&P Asia 50 ADR Index. From North Asia, the gainers were led by we
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
Asian equities traded in the US as American depositary receipts were higher in Wednesday trading, rising 1.04% to 2,008.61 on the S&P Asia 50 ADR Index. From North Asia, the gainers were led by live g
Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note
Asian equities traded in the US as American depositary receipts started the week flat Monday morning, nudging 0.005% higher to 1,959.42 on the S&P Asia 50 ADR Index. From North Asia, the gainers were
Dr. Reddy's to Co-market Zydus' Breast Cancer Treatment in India
Dr. Reddy's Laboratories (RDY) plans to co-market Zydus Lifesciences' Pertuzumab biosimilar to treat breast cancer patients in India. Zydus will market the product under the Sigrima brand name while D
Top Gap Ups and Downs on Thursday: MU, SONY, ZTS and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Express News | Dr. Reddy's Laboratories Shares Are Trading Higher After the Company Announced It Signed a Definitive Agreement With Haleon for Purchase of Shares of Northstar Switzerland SARL to Acquire Its Global Portfolio of Consumer Healthcare Brands in the...
Asian Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading
Asian equities traded in the US as American depositary receipts were flat in late Thursday morning trading, nudging 0.04% higher to 1,957.15 on the S&P Asia 50 ADR Index. From North Asia, the gainers
Dr. Reddy's to Acquire Haleon's Nicotine Replacement Therapy Business Outside US
Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124), through its Swiss arm, agreed to acquire British consumer healthcare company Haleon's nicotine replacement therapy business outside the US, accordin
Express News | Haleon Sells Its Nicotine Replacement Therapy Business Outside Of The U.S. To Dr. Reddy's Laboratories SA For Total Consideration Of £500 Million
Haleon to Sell Overseas Nicotine Therapy Business to Dr. Reddy's
Haleon to Sell Nicotine-Quitting Aid Business for $634 Million
By David Sachs Haleon will sell a significant portion of its nicotine-quitting aid business to Dr. Reddy's Laboratories, an India-based pharmaceutical company, in a 500 million-pound ($634.2 million)
Haleon: All Other 2024 Guidance Unchanged
Haleon: All Other 2024 Guidance Unchanged
Haleon: Sale Will Dilute 2024 Rev by 0.5%, Adj Oper Pft by 1%
Haleon: Sale Will Dilute 2024 Rev by 0.5%, Adj Oper Pft by 1%
Express News | Dr. Reddy's Laboratories Switzerland Acquires Haleon Group's Nicotine Replacement Therapy Brands Outside US for GBP 458M, Plus Up to GBP 42M in Contingent Payments in CY 2025 and CY 2026
Haleon: Sales Allow For NRT Exit Outside US, Trim Business Complexity
Haleon: Sales Allow For NRT Exit Outside US, Trim Business Complexity